Extracellular vesicles in prostate cancer: a narrative review

Hatano, Koji; Fujita, Kazutoshi

doi:10.21037/tau-20-1210

Cited by 20 publications

(15 citation statements)

References 187 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Authors demonstrated a novel association between high levels of AR-V7 exosomal mRNA (with undetectable androgen levels) and high neutrophil-to-lymphocyte ratio ( 26 ). High expression of full-length androgen receptor (AR-FL) was also linked with AR-V7+ CRPC patients and predicted resistance to hormonal therapy ( 84 , 85 ).…”

Section: Metastatic Prostate Cancer Biomarkers: Psa and Beyondmentioning

confidence: 99%

Liquid Biopsy Based Circulating Biomarkers in Metastatic Prostate Cancer

et al. 2022

View full text Add to dashboard Cite

Prostate cancer is the most dominant male malignancy worldwide. The clinical presentation of prostate cancer ranges from localized indolent to rapidly progressing lethal metastatic disease. Despite a decline in death rate over the past years, with the advent of early diagnosis and new treatment options, challenges remain towards the management of metastatic prostate cancer, particularly metastatic castration sensitive prostate cancer (mCSPC) and castration resistant prostate cancer (mCRPC). Current treatments involve a combination of chemotherapy with androgen deprivation therapy and/or androgen receptor signalling inhibitors. However, treatment outcomes are heterogeneous due to significant tumor heterogeneity indicating a need for better prognostic biomarkers to identify patients with poor outcomes. Liquid biopsy has opened a plethora of opportunities from early diagnosis to (personalized) therapeutic disease interventions. In this review, we first provide recent insights about (metastatic) prostate cancer and its current treatment landscape. We highlight recent studies involving various circulating biomarkers such as circulating tumor cells, genetic markers, circulating nucleic acids, extracellular vesicles, tumor-educated platelets, and the secretome from (circulating) tumor cells and tumor microenvironment in metastatic prostate cancer. The comprehensive array of biomarkers can provide a powerful approach to understanding the spectrum of prostate cancer disease and guide in developing improved and personalized treatments for patients.

show abstract

Section: Metastatic Prostate Cancer Biomarkers: Psa and Beyondmentioning

confidence: 99%

Liquid Biopsy Based Circulating Biomarkers in Metastatic Prostate Cancer

et al. 2022

View full text Add to dashboard Cite

show abstract

“…A more recent study supported the interest of urine EVs for the diagnosis of PCa, especially high-grade cancer [ 175 ]. Plasma and serum EVs have also been found as potential biomarkers for a PCa diagnosis [ 176 ]. In addition, tumor-derived EVs were found significantly higher in plasma from patients with CRPC and associated with a dimmer chance of survival [ 177 ].…”

Section: Emergent Role Of the Extracellular Vesicles In The Intercell...mentioning

confidence: 99%

Prostate Cancer Tumor Stroma: Responsibility in Tumor Biology, Diagnosis and Treatment

González

Eiró

Fraile

et al. 2022

Cancers

View full text Add to dashboard Cite

Prostate cancer (PCa) is a common cancer among males globally, and its occurrence is growing worldwide. Clinical decisions about the combination of therapies are becoming highly relevant. However, this is a heterogeneous disease, ranging widely in prognosis. Therefore, new approaches are needed based on tumor biology, from which further prognostic assessments can be established and complementary strategies can be identified. The knowledge of both the morphological structure and functional biology of the PCa stroma compartment can provide new diagnostic, prognostic or therapeutic possibilities. In the present review, we analyzed the aspects related to the tumor stromal component (both acellular and cellular) in PCa, their influence on tumor behavior and the therapeutic response and their consideration as a new therapeutic target.

show abstract

“…In this context, EVs isolated from liquid biopsies such as serum, plasma and urine, appear as an attractive source of material especially for prostate cancer personalized medicine. Over the past decade, urinary and blood based biomarkers from EVs have been described and used for diagnosis as well as for tumor progression prediction [102,103]. Among those biomarkers, some have been documented in relation to therapeutic resistances in PCa (Table 1).…”

Section: Evs As Source Of Biomarkers To Predict Therapeutic Resistances In Pca 41 Evs Content To Find New Predictive Biomarkersmentioning

confidence: 99%

Extracellular Vesicles in Advanced Prostate Cancer: Tools to Predict and Thwart Therapeutic Resistance

Saldana

Majidipur

Beaumont

et al. 2021

Cancers

View full text Add to dashboard Cite

Prostate cancer (PCa) is the second most frequent cancer and the fifth leading cause of cancer death among men worldwide. At first, advanced PCa is treated by androgen deprivation therapy with a good initial response. Nevertheless, recurrences occur, leading to Castrate-Resistance Prostate Cancer (CRPC). During the last decade, new therapies based on inhibition of the androgen receptor pathway or taxane chemotherapies have been used to treat CRPC patients leading to an increase in overall survival, but the occurrence of resistances limits their benefits. Numerous studies have demonstrated the implication of extracellular vesicles (EVs) in different cancer cellular mechanisms. Thus, the possibility to isolate and explore EVs produced by tumor cells in plasma/sera represents an important opportunity for the deciphering of those mechanisms and the discovery of biomarkers. Herein, we summarized the role of EVs in therapeutic resistance of advanced prostate cancer and their use to find biomarkers able to predict these resistances.

show abstract

Extracellular vesicles in prostate cancer: a narrative review

Cited by 20 publications

References 187 publications

Liquid Biopsy Based Circulating Biomarkers in Metastatic Prostate Cancer

Liquid Biopsy Based Circulating Biomarkers in Metastatic Prostate Cancer

Prostate Cancer Tumor Stroma: Responsibility in Tumor Biology, Diagnosis and Treatment

Extracellular Vesicles in Advanced Prostate Cancer: Tools to Predict and Thwart Therapeutic Resistance

Contact Info

Product

Resources

About